You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Antalarmin hydrochloride
Antalarmin hydrochloride is a non-peptide corticotropin-releasing hormone receptor 1 (CRF1) antagonist (Ki = 1 nM). Suppresses CRF-induced ACTH secretion. Blocks CRF- and novelty-induced anxiety-like behavior in animal models of anxiety.
Compound Libraries for Antalarmin hydrochloride
Technical Data for Antalarmin hydrochloride
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Antalarmin hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Antalarmin hydrochloride
The following data is based on the product molecular weight 415.01. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.41 mL||12.05 mL||24.1 mL|
|5 mM||0.48 mL||2.41 mL||4.82 mL|
|10 mM||0.24 mL||1.2 mL||2.41 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
Product Datasheets for Antalarmin hydrochloride
References for Antalarmin hydrochloride
References are publications that support the biological activity of the product.
Webster et al (1996) In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 5747 PMID: 8940412
Zorrilla et al (2002) Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952 188 PMID: 12376179
Specio et al (2008) CRF1 receptor antagonists attenuate ascalated cocaine self-administration in rats. Psychopharmacol. 196 473
If you know of a relevant reference for Antalarmin hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Antalarmin hydrochloride, Antalarmin hydrochloride supplier, CRF1, antagonists, Corticotropin-Releasing, Factor1, Receptors, 2778, Tocris Bioscience
4 Citations for Antalarmin hydrochloride
Citations are publications that use Tocris products. Selected citations for Antalarmin hydrochloride include:
Wood et al (2006) Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in rats. Neuropsychopharmacology 31 2580 PMID: 16710322
Gray et al (2015) Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci 35 3879 PMID: 25740517
Zhao-Shea et al (2015) Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. Front Cell Neurosci 6 6770 PMID: 25898242
Narla et al (2015) Suppression of piriform cortex activity in rat by corticotropin-releasing factor 1 and serotonin 2A/C receptors. Psychoneuroendocrinology 9 200 PMID: 26074770
Do you know of a great paper that uses Antalarmin hydrochloride from Tocris? Please let us know.
Reviews for Antalarmin hydrochloride
There are currently no reviews for this product. Be the first to review Antalarmin hydrochloride and earn rewards!
Have you used Antalarmin hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.